Take a look at our previous reports:
Annual Report
2021
View Report
Q1 Report
2022
View Report
H1 Report
2022
View Report
Q3 Report
2022
View Report
Annual Report 2022
Twitter
LinkedIn
en
English
Dutch
Hauptmenü
change report
English
Dutch
Home
The Galapagos group
Letter from the CEO and Chairman
Our Company
The year in review
Key achievements in 2022
Corporate and Operational Performance
Financial performance
The Galapagos share
Potential external impacts
Going concern statement
Risk management and internal control
Disclaimer and other information
Portfolio
Portfolio and
outlook 2023
Immunology
Small Molecules pipeline
Jyseleca® franchise
Our TYK2 program: GLPG3667
Our SIK program
CAR-T pipeline
GLPG5101 in refractory SLE
Oncology
Our differentiating approach
Pipeline CAR-T manufactured at point-of-care
GLPG5101: CD19 CAR-T in rrNHL
GLPG5201: CD19 CAR-T in rrCLL
GLPG5301: BCMA CAR-T in rrMM
Risk factors
Commercialization
Product development and regulatory approval
Financial position and need for additional capital
Reliance on third parties
Competitive position
Intellectual property
Organization, structure and operation
Galapagos shares
General statement
Sustainability report
Letter from the CEO
Our Materiality Assessment
Our Ambition
Our Sustainability Governance
Our Pillars
Patients
Our People
Planet
Trust & transparency
Reporting on EU Taxonomy
Corporate governance
Governance policy
Board of Directors
Committees
Executive Committee
Share capital and shares
Shareholders
Remuneration policy
Remuneration report
Introduction
Board of Directors
Executive Committee
Equity components of the remuneration
5-year evolution
Pay-ratio
Minimum share ownership
Provisions for severance
Claw-back right
Deviations from the remuneration policy
Conflict of interests and related parties
Code of Business Conduct and Ethics
Statement by the Board of Directors
Financial statements
Consolidated financial statements
Statements of income and comprehensive income/loss (-)
Statements of financial position
Cash flow statements
Statements of changes in equity
Notes to the consolidated financial statements
Notes 1-10
1.
General information
2.
Summary of significant transactions
3.
Significant accounting policies
4.
Critical accounting judgments and key sources of estimation uncertainty
5.
Segment information
6.
Total net revenues
7.
Operating costs and other operating income
8.
Staff costs
9.
Fair value adjustments, net currency exchange differences and other financial income/expenses
10.
Income taxes
Notes 11-20
11.
Income/loss (–) per share
12.
Goodwill and impairment of goodwill
13.
Intangible assets other than goodwill
14.
Property, plant and equipment
15.
Other non-current assets
16.
Research and development incentives receivables
17.
Inventories
18.
Trade and other receivables and other current assets
19.
Current financial investments
20.
Cash and cash equivalents
Notes 21-30
21.
Share capital
22.
Deferred tax
23.
Lease liabilities
24.
Trade and other liabilities and other non-current liabilities
25.
Deferred income
26.
Business combinations during the period
27.
Discontinued operations
28.
Note to the cash flow statement
29.
Off-balance sheet arrangements
30.
Contingent assets and liabilities
Notes 31-36
31.
Share based payments
32.
Related parties
33.
Consolidated companies as of 31 December 2022
34.
Financial risk management
35.
Statutory auditor’s remuneration
36.
Events after balance sheet date
Overview statutory results
Auditor's report
Report of the statutory auditor
Magazine
Leading the way
CAR-T at point-of-care
Living with RA & UC
The Galapagos group
Letter from the CEO and Chairman
Our Company
The year in review
Key achievements in 2022
Corporate and Operational Performance
Financial performance
The Galapagos share
Potential external impacts
Going concern statement
Risk management and internal control
Disclaimer and other information
Portfolio
Portfolio and
outlook 2023
Immunology
Small Molecules pipeline
Jyseleca® franchise
Our TYK2 program: GLPG3667
Our SIK program
CAR-T pipeline
GLPG5101 in refractory SLE
Oncology
Our differentiating approach
Pipeline CAR-T manufactured at point-of-care
GLPG5101: CD19 CAR-T in rrNHL
GLPG5201: CD19 CAR-T in rrCLL
GLPG5301: BCMA CAR-T in rrMM
Risk factors
Commercialization
Product development and regulatory approval
Financial position and need for additional capital
Reliance on third parties
Competitive position
Intellectual property
Organization, structure and operation
Galapagos shares
General statement
Sustainability report
Letter from the CEO
Our Materiality Assessment
Our Ambition
Our Sustainability Governance
Our Pillars
Patients
Our People
Planet
Trust & transparency
Reporting on EU Taxonomy
Corporate governance
Governance policy
Board of Directors
Committees
Executive Committee
Share capital and shares
Shareholders
Remuneration policy
Remuneration report
Introduction
Board of Directors
Executive Committee
Equity components of the remuneration
5-year evolution
Pay-ratio
Minimum share ownership
Provisions for severance
Claw-back right
Deviations from the remuneration policy
Conflict of interests and related parties
Code of Business Conduct and Ethics
Statement by the Board of Directors
Financial statements
Consolidated financial statements
Statements of income and comprehensive income/loss (-)
Statements of financial position
Cash flow statements
Statements of changes in equity
Notes to the consolidated financial statements
Notes 1-10
1.
General information
2.
Summary of significant transactions
3.
Significant accounting policies
4.
Critical accounting judgments and key sources of estimation uncertainty
5.
Segment information
6.
Total net revenues
7.
Operating costs and other operating income
8.
Staff costs
9.
Fair value adjustments, net currency exchange differences and other financial income/expenses
10.
Income taxes
Notes 11-20
11.
Income/loss (–) per share
12.
Goodwill and impairment of goodwill
13.
Intangible assets other than goodwill
14.
Property, plant and equipment
15.
Other non-current assets
16.
Research and development incentives receivables
17.
Inventories
18.
Trade and other receivables and other current assets
19.
Current financial investments
20.
Cash and cash equivalents
Notes 21-30
21.
Share capital
22.
Deferred tax
23.
Lease liabilities
24.
Trade and other liabilities and other non-current liabilities
25.
Deferred income
26.
Business combinations during the period
27.
Discontinued operations
28.
Note to the cash flow statement
29.
Off-balance sheet arrangements
30.
Contingent assets and liabilities
Notes 31-36
31.
Share based payments
32.
Related parties
33.
Consolidated companies as of 31 December 2022
34.
Financial risk management
35.
Statutory auditor’s remuneration
36.
Events after balance sheet date
Overview statutory results
Auditor's report
Report of the statutory auditor
Magazine
Leading the way
CAR-T at point-of-care
Living with RA & UC
Suche
Home
Privacy policy
Privacy policy
Downloads
Financial Calendar
Glossary of terms
